The controversial approval of Biogen's drug Aduhelm (aducanumab) in the US hasn't been followed by a corresponding approval in the EU, the company itself reports in a press release on Wednesday.
An oral presentation held by Biogen in November was followed by a so-called trend vote from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). It resulted in members of the committee adopting a negative opinion on the drug and thus no backing for a potential marketing approval in the EU. A formal rejection is expected to be announced at the CHMP's monthly meeting in December.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.